Rein Therapeutics (NASDAQ:RNTX) Price Target Cut to $8.00 by Analysts at HC Wainwright

Rein Therapeutics (NASDAQ:RNTX) had its target price lowered by stock analysts at HC Wainwright from $10.00 to $8.00 in a report released on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Separately, Wall Street Zen raised Rein Therapeutics to a “sell” rating in a research report on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $7.00.

Rein Therapeutics Stock Performance

Rein Therapeutics stock opened at $1.11 on Monday. The stock’s 50 day moving average price is $1.32 and its 200 day moving average price is $1.30. The firm has a market capitalization of $94.95 million, a PE ratio of -0.58 and a beta of 1.35. Rein Therapeutics has a one year low of $0.95 and a one year high of $2.18.

Rein Therapeutics (NASDAQ:RNTX) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.30. On average, analysts forecast that Rein Therapeutics will post -1.63 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Rein Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Chicago Partners Investment Group LLC raised its position in shares of Rein Therapeutics by 32.2% in the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock valued at $53,000 after purchasing an additional 10,000 shares in the last quarter. Gagnon Securities LLC raised its position in shares of Rein Therapeutics by 5.0% in the 4th quarter. Gagnon Securities LLC now owns 240,220 shares of the company’s stock valued at $279,000 after purchasing an additional 11,528 shares in the last quarter. Susquehanna International Group LLP acquired a new position in shares of Rein Therapeutics in the 3rd quarter valued at approximately $35,000. HRT Financial LP acquired a new position in shares of Rein Therapeutics in the 4th quarter valued at approximately $38,000. Finally, Geode Capital Management LLC raised its position in shares of Rein Therapeutics by 15.1% in the 4th quarter. Geode Capital Management LLC now owns 284,555 shares of the company’s stock valued at $330,000 after purchasing an additional 37,244 shares in the last quarter. 90.89% of the stock is owned by institutional investors and hedge funds.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.